Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
Hemant Surgical Industries receives order
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Subscribe To Our Newsletter & Stay Updated